Explore Topics

The future of eBV is here. How manufacturers can use AI to help patients start life-changing therapies faster than ever.

How do nurses make a difference when it comes to patient-centric adherence programs? A Lash Group nurse shares how she offers personal support for rare disease patients.

Executive Q&A: best practices for a patient support program launch.

Lash Group's nurse educators offer empathy, experience and expertise to help patients navigate the complexities of today's specialty therapies. Learn how they add critical value to adherence programs.

The growth of biosimilars presents a significant opportunity to reduce the cost of care and provide patients with greater access to affordable treatments. Our experts assess the current state and future of the biosimilars market.

How are biosimilar manufacturers approaching patients, providers and payers? What can they do to differentiate? Xcenda shares insight from our field programs.

An animated, immersive biosimilar market snapshot with actionable insight for manufacturers.

Innovative therapies make innovative patient services essential. Learn how Lash Group helped one manufacturer improve speed and access to therapy with an electronic provider portal for benefit verification and prior authorization.

What are the elements of innovative, effective medication adherence programs -- and how do they address the underlying causes of non-adherence?

In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?

Executive Q&A: The market trends and technology solutions impacting medication adherence today.

A collection of AmerisourceBergen's top insights from 2018, including commercialization considerations for novel therapies, emerging trends in retail and specialty pharmacy and best practices for managing inventory in the specialty practice.

How can FTZs help with commercialization success? What should manufacturers consider when evaluating a FTZ and 3PL partner?

What are FTZs and why should pharma use them?

Much of the complexity of the cell and gene supply chain comes from how dependent the commercialization phase is on the clinical phase. What does integration look like, and how can the right logistics partner help?

How third-party logistics (3PL) solutions can help cell and gene therapy manufacturers manage the financial aspects of launching new therapies.

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

How manufacturers can benefit from provider-led care coordination to improve patient outcomes.

How do channel strategy decisions impact providers and patients—and how can you ensure a patient-centric commercialization strategy? Our strategic global sourcing experts share insights on how customers respond to channel strategy decisions.

How is manufacturer thinking around channel strategy changing for oral oncolytics?

What manufacturers need to know about how distribution impacts access.

Insights from managed care executives on the future of coverage and outcomes evaluation.

How do manufacturers' distribution decisions ultimately impact patients? What long- and short-term disruption do direct models present? AmerisourceBergen experts offer perspective on the unintended consequences of channel strategy decisions.

Our strategic global sourcing experts share how AmerisourceBergen's leadership in specialty distribution influences the way we partner with manufacturers.

Our experts share what customers wish manufacturers knew about product access.

How can manufacturers approach reimbursement and patient support for cell and gene therapies and other medical innovations?

What manufacturers need to know about the customer experience.

What information do payers and providers want from pharma?

Key themes from ThinkLive 2017, AmerisourceBergen's annual manufacturer summit.

How pharmaceutical wholesalers have evolved in recent years.

What should biosimilar manufacturers focus on for commercialization success?

What does the future of benefit verification look like for manufacturer patient support programs?

Three factors that could influence biosimilars' commercial success.

Four things to keep in mind for patient support partnerships.

In supply chain decisions, a wholly new type of product demands a wholly new definition for supply chain expertise and effective support.

Learn what it takes to design an effective commercialization strategy and execute an integrated solution when the patient is in the supply chain.

Learn the unintended consequences of channel strategy decisions and the impact on patients and providers.

Explore what it means to put patients at the center of support program design through this interactive experience drawing perspective from real patients and how they view healthcare.

Demonstrate the value of rare disease therapies with these five key ways to connect where patients, physicians and payers perceive the most value.

New challenges to oncology product access, optimized clinical outcomes and commercial success, with strategic recommendations for how pharmaceutical manufacturers can support prescribers and patients through the continuum of cancer care.

Designing support programs that are truly patient-centric and overcoming obstacles along the way.

Mapping the patient journey and building support programs that address the three biggest hurdles patients face.

How can manufacturers turn patient-centricity from buzzword into reality?

Successful commercialization demands that manufacturers address three critical areas of opportunity — evidence, access and adherence.

The globalization of healthcare raises a number of questions for the pharmaceutical industry, from how R&D is changing to how to approach new markets.